Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients. As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. This first-in-class therapeutic offers hope for more durable remissions, as well as better quality of life, following a single infusion in a group of patients that previously had little hope. This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.

Original languageEnglish (US)
Pages (from-to)277-289
Number of pages13
JournalFuture Oncology
Issue number3
StatePublished - Jan 2022
Externally publishedYes


  • BB2121
  • CAR T cells
  • ide-cel
  • idecabtagene vicleucel
  • relapsed refractory myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this